Clinical Trial Update: Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Ad/HER2/Neu dendritic cell cancer vaccine in HER2/Neu-expressing breast cancer to assess safety and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinomas
• Breast Cancer
• Solid Tumors Characterized By HER2 Neu Expression

Drugs mentioned

• Ad/HER2/Neu dendritic cell cancer vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Neoplasms, Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2022-09-10